Several other equities analysts have also weighed in on PRPH. TheStreet lowered shares of ProPhase Labs from a b rating to a c+ rating in a research report on Tuesday, August 23rd. Dawson James lowered shares of ProPhase Labs from a neutral rating to a sell rating in a research report on Thursday, July 21st. Finally, HC Wainwright increased their price objective on shares of ProPhase Labs from $14.00 to $15.00 and gave the company a buy rating in a research report on Friday.
ProPhase Labs Price Performance
Shares of PRPH opened at $11.96 on Monday. The firm has a market capitalization of $191.43 million, a PE ratio of 6.57 and a beta of -0.27. The company’s 50-day moving average is $11.11 and its 200-day moving average is $10.82. ProPhase Labs has a fifty-two week low of $5.55 and a fifty-two week high of $15.25. The company has a debt-to-equity ratio of 0.12, a current ratio of 4.20 and a quick ratio of 3.93.
Hedge Funds Weigh In On ProPhase Labs
About ProPhase Labs
ProPhase Labs, Inc engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.
- Get a free copy of the StockNews.com research report on ProPhase Labs (PRPH)
- Wayfair Still Has Its Fair Share of Issues
- Take Two Interactive Software Stock is Taking One Step Back
- This Mid-Cap Tech Stock Embodies Diversified Growth
- Why did NIO take a $581.11 million loss last quarter?
- Is It Time To Take A Ride With Joby Aviation’s EV Innovations?
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.